JOHNSON + JOHNSON DL 1
Commented by Nico Popp on June 10th, 2026 | 08:25 CEST
Dividend Strategies Put to the Test: Margin Pressure at McDonald's and Johnson & Johnson – RE Royalties Shows Resilience in a Crisis
Global capital markets are undergoing a significant transformation. What generated returns yesterday may already be risky today. For decades, established consumer goods brands and research-intensive pharmaceutical companies were considered the robust cornerstones of dividend strategies. But this paradigm is coming under increasing pressure. Rising operating costs, regulatory interventions, and the relentless cycle of patent expirations are challenging even the most resilient market leaders. In this market environment, alternative financing models with an asset-light approach are gaining importance. Natural energy sources such as wind and solar power offer the opportunity for stable, recurring, and above all inflation-protected revenue streams through innovative royalty structures. That is exactly what investors are looking for right now. We provide an overview.
Read
Commented by Nico Popp on July 10th, 2025 | 07:25 CEST
Small-cap disrupts billion-dollar market: Johnson & Johnson, Merck KGaA, and NetraMark
When it comes to making people healthy, progress is what matters most. New drugs must be better and safer than old ones. To ensure that these requirements are met, comprehensive testing procedures are carried out by drug regulatory authorities. However, despite ever-expanding knowledge and modern methods, almost 90% of clinical trials still fail. When considering that the development of a drug costs an average of USD 2.6 billion and usually takes more than ten years, it becomes clear what a risk biotech companies and pharmaceutical multinationals are taking. This is precisely where NetraMark's business model comes in, offering the entire industry unparalleled leverage.
Read
Commented by Mario Hose on January 12th, 2022 | 10:53 CET
Trading stocks after EMA warning in focus: BioNTech, Johnson + Johnson, Moderna
On Wednesday, the German indices began with a positive sign. The German benchmark index DAX is currently quoted at a level of 16,004 points and thus around 0.04% slightly up. The companies in the second tier can also hold their ground and the MDAX last traded at 34,864 points (+0.26%), TexDAX at 3,644 points and thus 0.60% lower than the previous day. SDAX also loses and last traded at 15,969 points (-0.23%).
Read
Commented by Nico Popp on April 13th, 2021 | 08:43 CEST
Johnson + Johnson, Pollux Properties, Home24: Tide is turning - where the returns are now waiting
The pandemic continues to smolder. Billion-dollar investments in the healthcare sector will continue to be necessary for the coming years and companies in the healthcare sector can look forward to increasing demand for years to come. The consequences of the pandemic also affect other areas: In addition to the geopolitical balance of power, the pandemic has also changed consumer behavior. Three stocks in check - who will profit after the pandemic?
Read
Commented by Nico Popp on February 4th, 2021 | 08:15 CET
BioNTech, Cardiol Therapeutics, Johnson & Johnson: biotech gems from the well-known to the unknown
If there's one industry that's rightfully making big profits these days, it's healthcare companies. The pandemic has kissed the industry awake. In addition to the current relevance around Covid treatment, test procedures, or even vaccinations, there is also a growing awareness that medical innovation depends on research. More and more investors are willing to push promising projects and the general conditions for this could not be better. There is a consensus in politics, society and business that health is the highest good.
Read
Commented by Nico Popp on January 19th, 2021 | 10:50 CET
Pfizer, Q&M Dental Group, Johnson & Johnson: Where do profiteers of the pandemic lurk?
We all know that one's health is the most important thing. But from time to time, this truism slips out of focus. The pandemic has shown that neither fame nor money can protect you from getting sick. A big step toward being healthy, however, can be made by trusting in research. The development of vaccines in record time has shown how great the potential is in science and the pharmaceutical industry. New test methods are continually coming onto the market. Three shares show that there is money to be made on the stock market from these developments.
Read
Commented by Mario Hose on April 16th, 2020 | 07:55 CEST
Johnson & Johnson, Memphasys, Procter & Gamble - for a better life
Good health is a valuable possession. Small and large companies around the globe are engaged in research and development to make people's lives easier or better through modern and innovative products and solutions. The consumer goods and pharmaceutical sectors often offer attractive opportunities for investors to generate a lucrative return. Well-known companies with established brands usually ensure lasting sales. However, promising young companies also use innovations to attract the attention of investors and customers.
Read